Meeting Overview - The first meeting of the 10th Board of Directors of China National Pharmaceutical Group Co., Ltd. was held on February 9, 2026, combining in-person and communication methods [2] - All 8 directors attended the meeting, and the meeting complied with the relevant provisions of the Company Law and Articles of Association, making the resolutions valid [4][5] Resolutions Passed - The board elected Mr. Yang Guang as the Chairman and legal representative of the company, with a term from the date of approval until the end of the 10th Board's term [6] - The board approved the election of members for various specialized committees, including: - Strategy and ESG Committee: Mr. Yang Guang (Chairman), Mr. Pan Zhen, Mr. Li Zhiyong, Mr. Fan Xiongtao - Audit and Risk Control Committee: Mr. Wang Ruihua (Chairman), Ms. Yan Yonghong, Mr. Fan Xiongtao - Nomination Committee: Ms. Yan Yonghong (Chairman), Mr. Wang Ruihua, Mr. Yang Guang - Compensation and Assessment Committee: Mr. Li Zhiyong (Chairman), Mr. Wang Ruihua, Ms. Sun Zhuo [8][10] - The board appointed Mr. Yang Guang as the General Manager, with a term from the date of approval until the end of the 10th Board's term [12] - The board approved the appointment of senior management personnel, including: - Mr. Zhang Peng and Mr. Chen Jianxiong as Vice General Managers - Ms. Ge Xiaohong as Chief Accountant - Mr. Zhang Huibo and Mr. Lü Heping as Assistant General Managers - Mr. Zhang Jian as Chief Legal Advisor [14][15] - The board appointed Mr. Yuan Jinghua as the Secretary of the Board and Ms. Guo Fan as the Securities Affairs Representative [17][19] - The board approved the renewal of the office lease for the General Times Center for one year, with a total rental amount not exceeding 62.2451 million yuan (including tax) [21][37] Office Lease Details - The lease agreement is with China General Technology (Group) Holding Limited and its property management company, covering the period from January 1, 2026, to December 31, 2026 [37] - The total rental and property service fees are expected to be no more than 72.1593 million yuan [37] - The rental price remains unchanged compared to 2025, based on market pricing and surrounding office buildings [39][52] New Drug Registration - The company’s subsidiary, Tianfang Pharmaceutical Co., Ltd., received two drug registration certificates for fumaric acid volnoreline tablets from the National Medical Products Administration [64] - The drug is primarily used for treating reflux esophagitis and eradicating Helicobacter pylori when used with appropriate antibiotics [65] - The total investment in the drug's raw materials and formulation projects is approximately 12.32 million yuan [67] - The market for this drug is projected to have sales of approximately 774 million yuan in 2024 and 778 million yuan in the first three quarters of 2025 [68]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ●本次会议是否有否决议案：无 一、会议召开和出席情况 登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：600572 证券简称：康恩贝 公告编号：2026-013 浙江康恩贝制药股份有限公司 2026年第一次临时股东会决议公告 ■ （四）表决方式是否符合《公司法》及《公司章程》的规定，会议主持情况等。 本次股东会由浙江康恩贝制药股份有限公司（以下简称"公司"）董事会召集，因董事长出差在外，会议 由公司副董事长金军丽主持。本次股东会采取现场会议表决和网络投票表决相结合的方式召开。会议的 召集、召开及表决程序符合《公司法》《公司章程》等相关法律、法规的规定。 （五）公司董事和董事会秘书的列席情况 1、公司在任董事9人，列席6人，董事长应徐颉、非独立董事吴律文、独立董事牛宇龙因出差在外未能 参加本次会议； 2、副总裁、董事会秘书金祖成出席了本次会议，副总裁谌明、尹石水列席本次会议。 二、议案审议情况 （一）非累积投票议案 （一）股东会召开的时间：2026年2月 ...

Overview - Guangdong Zhongsheng Pharmaceutical Co., Ltd. has approved the use of idle self-owned funds for entrusted wealth management, with a limit of up to RMB 400 million for a period of twelve months [2] Investment Details - The company’s wholly-owned subsidiary, Guangdong Zhongsheng Pharmaceutical Trading Co., Ltd., has signed an agreement with Dongguan Branch of Bank of Communications to invest RMB 50 million in a structured deposit product [2] - The product is a principal-protected floating return type, with a term of 22 days and an expected annualized return rate of 1.00% to 2.10% [4][2] Risk Control Measures - The company will adhere to prudent investment principles and strictly follow the board-approved investment limits [8] - Regular market analysis and adjustments to investment strategies will be conducted to mitigate risks [8] - A detailed management system for entrusted wealth management has been established to prevent investment risks [8] Impact on the Company - The company aims to enhance the efficiency of idle funds and improve cash asset returns without affecting normal business operations [9] - Engaging in wealth management is expected to contribute positively to the overall performance of the company and benefit all shareholders [9]

Core Viewpoint - Beijing Zhongguancun Science and Technology Development (Holding) Co., Ltd. announced that its subsidiary, Beijing Huasu Pharmaceutical Co., Ltd., has successfully passed the consistency evaluation for the generic drug Tramadol Hydrochloride Tablets (50mg) [1][2]. Group 1: Drug Approval Details - The drug name is Tramadol Hydrochloride Tablets, in tablet form, with a specification of 50mg [1]. - The approval notice number is 2026B00624, and the drug is classified as a chemical drug [1]. - The approval includes changes to the prescription, manufacturing process, production batch, quality standards, and shelf life [1]. Group 2: Market Context - The original drug has not been marketed in China, but there are currently eight generic versions approved, with three having passed the consistency evaluation [2]. - Beijing Huasu is the third domestic company to receive approval for this drug's consistency evaluation [2]. Group 3: Financial Investment - The total research and development investment for the consistency evaluation project of Tramadol Hydrochloride Tablets has reached approximately 5.9 million yuan [3]. Group 4: Impact on Company Performance - The approval is expected to enhance the market competitiveness of the drug and positively impact the company's operating performance [5]. - The company emphasizes the importance of drug research and development, maintaining strict quality control throughout the drug development, manufacturing, and sales processes [5].

Group 1 - The company held its 45th meeting of the 8th Board of Directors on February 9, 2026, via communication methods [3][5] - All 9 directors participated in the voting process, with unanimous approval for the resolutions [4][7] - The meeting was chaired by acting chairwoman Zhang Li, and senior management attended [5] Group 2 - The board approved the nomination of Ms. Li Xiaoguang as an independent director candidate, who meets the qualifications set by relevant regulations [6] - Upon approval by the shareholders' meeting, Ms. Li will also serve as the chair of the Compensation and Assessment Committee and a member of the Nomination Committee [6] - The independent director candidate's qualifications will be subject to review by the Shenzhen Stock Exchange before being submitted for shareholder approval [6] Group 3 - Ms. Li Xiaoguang has a distinguished background, including roles in arbitration and legal advisory, and has received multiple accolades for her contributions [10] - She does not hold any shares in the company and has no relationships with major shareholders or other board members [11] - Ms. Li's qualifications comply with the requirements of the Company Law and relevant regulations [11]

Core Viewpoint - The company has received a drug registration certificate for Tadalafil 20mg tablets from the Ghana Food and Drug Administration, marking a significant step in its international market expansion [1][3]. Group 1: Drug Registration Details - Drug Name: TADALAFIL 20mg TABLETS - Dosage Form: Tablet - Specification: 20mg - Registration Number: FDA/GD.255-120251 - Certificate Number: FDA-GH-77157971 - Manufacturer: Jiangsu Lianhuan Pharmaceutical Co., Ltd. - Address: No. 9, Health Road, Yangzhou Biohealth Industry Park, Yangzhou, Jiangsu Province - Validity Period: Until December 31, 2030 [1]. Group 2: Market Position and Financial Impact - The company is the only Chinese enterprise holding the Tadalafil 20mg drug registration certificate in Ghana [2]. - The sales revenue for Tadalafil tablets in 2024 is projected to be 23.0793 million RMB [1]. - The registration allows for legal sales in Ghana, but the expected revenue impact on the company's overall performance is minimal due to the current lack of sales in the region [3].

Core Viewpoint - The announcement details the completion of additional share pledges by the controlling shareholder of Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd., aimed at securing a bond issuance, with significant implications for the company's financial stability and shareholder structure [1][2]. Group 1: Share Pledge Details - As of February 5, 2026, the controlling shareholder, Heilongjiang Chuangda Group Co., Ltd., holds 523,231,148 shares, representing 55.60% of the total share capital, with 421,115,848 shares pledged, accounting for 80.48% of its holdings [2][4]. - The controlling shareholder has pledged an additional 1,170,000 shares to secure the 23 Chuang 02EB bond, with the pledge completed on February 6, 2026 [3][4]. - The total number of pledged shares has decreased due to a bond conversion, with the previous pledge count adjusted accordingly [4]. Group 2: Financial Health and Risk Assessment - The controlling shareholder has no significant litigation or arbitration issues related to debt, and its operational and performance status is normal, with debt repayment sources identified [9][10]. - The controlling shareholder's total outstanding exchangeable bonds amount to 427.25 million yuan, with no immediate repayment risks identified [9]. - The company assesses that the current pledge situation does not pose a risk of forced liquidation or transfer, and the controlling shareholder is expected to take proactive measures if necessary [10].

Core Viewpoint - Ningbo Meinuo Pharmaceutical Co., Ltd. plans to repurchase and cancel a total of 181,100 restricted stocks due to the departure of 17 incentive targets from the 2024 stock incentive plan, in accordance with the relevant provisions of the plan and the authorization from the 2023 annual general meeting [2][3]. Group 1: Repurchase and Cancellation Details - The decision for the repurchase and cancellation of restricted stocks was approved at the 21st meeting of the fifth board of directors held on December 15, 2025 [3]. - The repurchase price is set at 6.52 yuan per share, totaling 1,180,772 yuan for the repurchase [3]. - The repurchase funds will be sourced from the company's own funds [4]. Group 2: Legal and Regulatory Compliance - The company has fulfilled its obligation to notify creditors regarding the reduction of registered capital due to the repurchase and cancellation of shares [4]. - No creditors raised objections or requested debt repayment within the stipulated time frame [4]. - The company has confirmed that the decision-making process and information disclosure comply with relevant laws and regulations [8]. Group 3: Impact on Share Structure - Following the repurchase and cancellation, the total number of shares will decrease from 220,631,264 to 220,450,164 [7]. - The registered capital will also be reduced from 220,631,264 yuan to 220,450,164 yuan [7]. - After the cancellation, the remaining restricted stocks held by the involved personnel will be zero, while the company will have 4,254,280 shares of restricted stocks remaining [6].

Financial Performance Summary - The company reported preliminary financial data for the year 2025, indicating stable revenue growth from core industrial enterprises and improved profitability [1] - The acquisition of stakes in two subsidiaries, Hunan Qianjin Xiangjiang Pharmaceutical Co., Ltd. (28.92% stake) and Hunan Qianjin Xieli Pharmaceutical Co., Ltd. (68% stake), contributed to the financial performance starting from October and November 2025 respectively [1] Financial Data and Indicators - The financial data for 2025 is presented in yuan, but specific numerical values are not disclosed in the announcement [1]

关于磐石子公司完成工商登记并取得营业执照的公告 吉林省西点药业科技发展股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 吉林省西点药业科技发展股份有限公司（以下简称"公司"）于2026年1月22日召开了第八届董事会第十 四次会议，审议通过了《关于拟设立全资子公司的议案》，同意公司拟使用自有资金200万元人民币在 吉林省磐石市投资设立全资子公司西点大药房有限公司（暂定名，最终以市场监督管理部门核准结果为 准，以下简称"西点大药房"），并授权公司管理层办理西点大药房的设立登记事宜。授权有效期自董事 会审议通过之日起至工商变更登记及章程备案办理完毕之日止。具体内容详见公司在巨潮资讯网上披露 的《关于拟设立全资子公司的公告》（公告编号：2026-006）。 近日，公司完成了相关工商登记手续，并取得了磐石市市场监督管理局颁发的《营业执照》。相关工商 登记信息如下： 登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：301130 证券简称：西点药业 公告编号：2026-011 住所：吉林市磐石市开发区吉林省西点药业科技发展股份有限公司-原料粗品合成车 ...